Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults
Phase 1
Completed
- Conditions
- Cytomegalovirus Infections
- Interventions
- Drug: VBI-1501A 2.0 μgDrug: VBI-1501A 0.5 μgDrug: VBI-1501A 1.0 μgDrug: VBI-1501 1.0 μgDrug: Placebo
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- VBI Vaccines Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT02826798
- Locations
- 🇨🇦
Canadian Center for Vaccinology; IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦Vaccine Evaluation Center, Vancouver, British Columbia, Canada
🇨🇦McGill University Health Centre - Vaccine Study, Pierrefonds, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath